Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
  • SBI Life
  • DSP Mutual Fund
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now

Buy HealthCare Global Enterprises; target of Rs 375: Prabhudas Lilladher

Prabhudas Lilladher is bullish on HealthCare Global Enterprises has recommended buy rating on the stock with a target price of Rs 375 in its research report dated November 14, 2022.

November 29, 2022 / 04:14 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Prabhudas Lilladher's research report on HealthCare Global Enterprises

HCG’s consolidated post IND AS EBITDA grew healthy 21% YoY (4% QoQ) to Rs 747mn, in line with our estimates (Rs754mn). Adjusted for one time consulting (Rs50mn) and ESOP related charges (Rs12.9mn); was up by 28% YoY. Existing centers reported strong profitability with EBITDA growth of 30% YoY (4% QoQ) to Rs777mn, while new centers reported EBITDA at Rs 95mn (Rs 195mn in H1FY23). Margins improved by 10bps QoQ (25bps YoY) to 17.8% on cost rationalization initiatives. Margins adjusted for one off were at 19.3%. HCG’s asset light approach with focus on partnering has made its business model – capital efficient and scalable. The company operates most of its Comprehensive Cancer Centre (CCC) on lease/rental basis with HCG investing only in equipment’s. Out of 25 HCG’s CCC, only four are on owned land. HCG is in a consolidation mode and given reducing capex intensity, we expect profitability to improve further. Our FY23E and FY24E EBITDA stands increase by ~4-5%. We expect a 27% EBITDA CAGR over FY22-25E after adjusting for IND AS. At CMP, the stock trades at 15x FY24E EV/EBITDA adjusted for rentals.

Outlook

We maintain ‘Buy’ rating with revised TP of Rs375 (Rs358 earlier) valuing at 18x FY24E EV/EBITDA.